No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AZN250103C61000
- 5.18
- 0.000.00%
15min DelayTrading Jan 3 15:59 ET
0.00High0.00Low
0.00Open5.18Pre Close0 Volume0 Open Interest61.00Strike Price0.00Turnover6384.91%IV-1.17%PremiumJan 3, 2025Expiry Date5.97Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8393Delta0.0422Gamma12.93Leverage Ratio-1035.8075Theta0.0000Rho10.85Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
AstraZeneca (AZN) Gets a Buy From J.P. Morgan
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
AstraZeneca PLC Stock Flat Friday
AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.
AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.
Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6
EST Jan 2nd Afternoon Delivery - In the last two hours of trading, 4 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.